Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: Efficacy and incidence of cardiac and other events in elderly patients (≥65 years old)

Journal of Cardiology

Volumn 57, Issue 1, 2011, Pages 77-88

  Itakura, Hiroshige ^a   Nakaya, Noriaki ^b   Kusunoki, Tadashi ^c   Shimizu, Naokata ^d   Hirai, Shunsaku ^e   Mochizuki, Seibu ^f   Ishikawa, Toshitsugu ^g  

^a IBARAKI CHRISTIAN UNIVERSITY   (Japan)

^b Nakaya Clinic   (Japan)

^c Japanese Society for Pharmacoepidemiology   (Japan)

^d TEIKYO UNIVERSITY   (Japan)

^e Geriatrics Research Institute and Hospital   (Japan)

^f MUSASHINO UNIVERSITY   (Japan)

^g SONY CORPORATION   (Japan)

Author keywords

Elderly; Fluvastatin; Hypercholesterolemia; Local event monitoring; Safety

Indexed keywords

FLUINDOSTATIN; GAMMA GLUTAMYLTRANSFERASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EVENING DOSAGE; FATIGUE; FEMALE; GASTRITIS; GERIATRIC PATIENT; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPESTHESIA; INCIDENCE; JAPANESE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; MYALGIA; NAUSEA; PRIMARY PREVENTION; PRURITUS; RASH; SECONDARY PREVENTION; SIDE EFFECT; STOMACH DISCOMFORT; UPPER ABDOMINAL PAIN;

AGE FACTORS; AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHOLESTEROL; CHOLESTEROL, LDL; DRUG MONITORING; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 78650555966     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2010.09.003     Document Type: Article

References (35)

1. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
2. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307. For the West of Scotland Coronary Prevention Study Group.
3. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009. For the Cholesterol and Recurrent Events Trial Investigators.
4. Matsuzaki M., Kita T., Mabuchi H., Matsuzawa Y., Nakaya N., Oikawa S., Saito Y., Sasaki J., Shimamoto K., Itakura H. Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 2002, 66:1087-1095. J-LIT Study Group.
5. Nakamura H., Arakawa K., Itakura H., Kitabatake A., Goto Y., Toyota T., Nakaya N., Nishimoto S., Muranaka M., Yamamoto A., Mizuno K., Ohashi Y., MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006, 68:1155-1163.
6. Good Post-marketing Surveillance Practice regulations, version 10. Japanese Ministry of Health and Welfare; March 10, 1997.
7. Guidelines for the treatment of hyperlipidemia. J Jpn Atheroscler Soc 1997, 25:1-34. Japan Atherosclerosis Society (JAS).
8. Practice guide for obesity 1993, Japan Society for the Study of Obesity (JASSO), Ishiyaku Publishers Inc., Tokyo, p. 27-37.
9. Matsuzawa Y., Kita T., Mabuchi H., Matsuzaki M., Nakaya N., Oikawa S., Saito Y., Sasaki J., Shimamoto K., Itakura H, J-LIT Study Group Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J 2003, 67:287-294.
10. Mills E.J., Rachlis B., Wu P., Devereaux P.J., Arora P., Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008, 52:1769-1781.
11. Holdaas H., Wanner C., Abletshauser C., Gimpelewicz C., Isaacsohn J. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol 2007, 117:64-74.
12. Jardine A.G., Holdaas H., Fellström B., Cole E., Nyberg G., Grönhagen-Riska C., Madsen S., Neumayer H.H., Maes B., Ambühl P., Olsson A.G., Holme I., Fauchald P., Gimpelwicz C., Pedersen T.R. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant 2004, 4:988-995. ALERT Study Investigators.
13. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., Branzi A., Bertolami M.C., Jackson G., Strauss B., Meier B., Lescol Intervention Prevention Study (LIPS) Investigators Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 287:3215-3222.
14. Lerakis S., El-Chami M.F., Patel A.D., Veledar E., Alexopoulos E., Zacharoulis A., Triantafyllou A. Effect of lipid levels and lipid-lowering therapy on restenosis after coronary artery stenting. Am J Med Sci 2006, 331:270-273.
15. Lemos P.A., de Feyter P.J., Serruys P.W., Saia F., Arampatzis C.A., Disco C., Mercado N., Mainar V., Morís C., van den Bos A.A., Berghoefer G. Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease. Int J Cardiol 2005, 98:479-486.
16. Riegger G., Abletshauser C., Ludwig M., Schwandt P., Widimsky J., Weidinger G., Welzel D. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999, 144:263-270.
17. Herd J.A., Ballantyne C.M., Farmer J.A., Ferguson J.J., Jones P.H., West M.S., Gould K.L., Gotto A.M. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997, 80:278-286.
18. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
19. Lye M., Valacio R., Reckless J.P., Ghosh A.K., Findlay I.N., Ghosh M.K., Passmore A.P., Fulcher R.A. Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin. Coron Artery Dis 1998, 9:583-590.
20. Bruckert E., Verpilleux M.P., Dejager S., Isaacsohn J. Comparison of efficacy and safety assessment of fluvastatin in patients <65 years versus ≤65 years of age. Am J Cardiol 2005, 96:1142-1148.
21. Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K., Wilhelmsen L., Haghfelt T., Thorgeirsson G., Pyörälä K., Miettinen T., Christophersen B., Tobert J.A., Musliner T.A., Cook T.J. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998, 97:1453-1460. For the Scandinavian Simvastatin Survival Study Group.
22. Sacks F.M., Moyé L.A., Davis B.R., Cole T.G., Rouleau J.L., Nash D.T., Pfeffer M.A., Braunwald E. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998, 97:1446-1452.
23. Inami S., Okamatsu K., Takano M., Takagi G., Sakai S., Sano J., Mizuno K. Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia. Jpn Heart J 2004, 45:969-975.
24. Hussein O., Schlezinger S., Rosenblat M., Keidar S., Aviram M. Reduced susceptibility of low density lipoprotein to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997, 128:11-18.
25. Yokoyama H., Kawasaki M., Ito Y., Minatoguchi S., Fujiwara H. Effects of fluvastatin on the carotid arterial media as assessed by integrated backscatter ultrasound compared with pulse-wave velocity. J Am Coll Cardiol 2005, 46:2031-2037.
26. Corsini A., Pazzucconi F., Arnaboldi L., Pfister P., Fumagalli R., Paoletti R., Sirtori C.R. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 1998, 31:773-778.
27. Schartl M., Bocksch W., Koschyk D.H., Voelker W., Karsch K.R., Kreuzer J., Hausmann D., Beckmann S., Gross M. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001, 104:387-392. for the German Atorvastatin Intravascular Ultrasound Study Investigators (GAIN).
28. Abe K., Nakayama M., Yoshimura M., Nakamura S., Ito T., Yamamuro M., Sakamoto T., Miyamoto Y., Yoshimasa Y., Saito Y., Nakao K., Yasue H., Ogawa H. Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: a relation with the -786T>C polymorphism. Pharmacogenet Genomics 2005, 15:329-336.
29. Morishita R. Statin biology beyond cholesterol lowering: hepatic statins vs. vascular statins. Immunol Endocr Metab Agents Med Chem 2008, 8:103-104.
30. Yasue H., Mizuno Y., Harada E., Itoh T., Nakagawa H., Nakayama M., Ogawa H., Tayama S., Honda T., Hokimoto S., Ohshima S., Hokamura Y., Kugiyama K., Horie M., Yoshimura M., et al. Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol 2008, 51:1742-1748.
31. Schmidt G.A., Hoehns J.D., Purcell J.L., Friedman R.L., Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med 2007, 20:411-416.
32. Murinson B.B., Maragakis N.J., Jacobson T.A. Fluvastatin, rhabdomyolysis, and myotoxicity. Mayo Clin Proc 2008, 83:1296.
33. Basic-Jukic N., Kes P., Bubic-Filipi L., Vranjican Z. Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and rapamycin in a renal transplant recipient. Nephrol Dial Transplant 2010, 25:2036.
34. Jacobson T.A. Toward " pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008, 83:687-700.
35. Silva M., Matthews M.L., Jarvis C., Nolan N.M., Belliveau P., Malloy M., Gandhi P. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007, 29:253-260.